
The new agents in Diabetes – when should I take them?
The SGLT-2 Inhibitors have been around for a few years (Empagliflozin, Canagliflozin, Dapaglif lozin). The data on cardiovascular benefits are increasing, but as with all powerful drugs, they cant be used in all patients. They are useful in a type 2 ...
Read More







